About: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $33.58 (+2.32%)
PHVS NASDAQ Pharvaris BV
Pharvaris BV share price
Atividade de preço de PHVS
Último preço
$ 33,580
Variação (24h)
0,76 USD (2,32%)
Volume
874.09K
Volume (média 4 sem.)
-
Abertura
$ 32,84
Variação do dia
$ 32,70 - $ 33,58
Fechamento anterior
$ 32,82
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
PHVS price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals